ascopubs.org

A phase 1/2 study of KSQ-004EX: Autologous tumor infiltrating lymphocytes, engineered to inactivate genes encoding SOCS1 and Regnase-1, in patients with select advanced solid ...

Autologous tumor-infiltrating lymphocytes (HS-IT101) with low-dose lymphodepletion and IL-2 infusion for the treatment of advanced solid tumors: A phase I clinical trial. This is an ASCO Meeting ...
ascopubs.org

Phase I study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors.

Phase I study of the combination of alisertib (MLN8237) and gemcitabine in advanced solid tumors. This is an ASCO Meeting Abstract from the 2020 ASCO Annual Meeting I. This abstract does not include a ...